Interestingly, the knockdown of ITGB1 profoundly enhanced the antitumor effects of sorafenib (Figure 3B), suggesting that a high level of ITGB1 expression led to reduced sensitivity of HCC cells to antitumor drugs. This evidence concerns the gene ITGB1 and hepatocellular carcinoma.